- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02726919
Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy
Prospective Open Label Evaluation of Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy: A Pilot Study
The goal of the present study is to obtain pilot data on efficacy and safety of clobazam add-on treatment on adults with drug-resistant focal epilepsy.
This will be an open label study comparing seizure frequency during 12 weeks of baseline observation period with seizure frequency during 16 weeks of clobazam adjunctive treatment. 10 adults aged 18-65 with focal seizures that have failed to respond to ≥ 4 antiepileptic drugs (AEDs) +/- respective surgery will be enrolled. Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first. Titration rate will be not be forced. It is anticipated that the majority of subjects will have a 4 week-long titration period. After maximum dose is achieved, maintenance treatment will last for 12 weeks.
Study Overview
Detailed Description
Approximately 35 % of patients with epilepsy do not respond to treatment with medications. There is a need for new treatment of refractory focal epilepsy. Clobazam was approved in 2011 in the US for treatment of refractory seizures in patients with Lennox Gastaut syndrome (LGS). Patients with LGS have different seizure types. While pivotal studies evaluated primary generalized seizures, LGS patients also have focal seizures. The goal of the present study is to obtain pilot data on efficacy and safety of clobazam add-on treatment on adults with drug-resistant focal epilepsy.
This will be an open label study comparing seizure frequency during 12 weeks of baseline observation period with seizure frequency during 16 weeks of clobazam adjunctive treatment. 10 adults aged 18-65 with focal seizures that have failed to respond to ≥ 4 antiepileptic drugs (AEDs) +/- respective surgery will be enrolled. Following a baseline of 12 weeks, patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first. Titration rate will be not be forced. It is anticipated that the majority of subjects will have a 4 week-long titration period. After maximum dose is achieved, maintenance treatment will last for 12 weeks.
Primary efficacy outcome measure will be seizure freedom for 3 months of maintenance treatment with the highest tolerated clobazam dose. Secondary outcome measures will include >75% seizure frequency reduction and median seizure frequency reduction for the whole treatment duration and for the maintenance treatment period, comparing seizure frequency per 28 day periods during treatment vs. baseline. Primary safety outcome measures will include treatment emergent adverse events, and treatment discontinuation due to treatment emergent adverse events.
The number of subjects will be small, n=10. It is therefore likely that results obtained in the present study will not be statistically significant. The goal of the present study is to ascertain whether clobazam add-on treatment in adults with refractory focal epilepsy gives a signal of efficacy greater than that demonstrated with other second and third generation anticonvulsants such as levetiracetam, pregabalin, lacosamide and perampanel; specifically whether clobazam adjunctive treatment shows a trend towards 75% response and seizure freedom rate that surpasses those seen in phase 3 levetiracetam, pregabalin, lacosamide and perampanel studies. The results, if positive, will be used to design a larger controlled study would follow.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Pavel Klein, M.D.
- Phone Number: 3015309744
- Email: kleinp@epilepsydc.com
Study Contact Backup
- Name: Ivana Tyrlikova, M.D.
- Phone Number: 2404089665
- Email: tyrlikovai@epilepsydc.com
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- Recruiting
- Midatlantic Epilepsy and Sleep Center
-
Principal Investigator:
- Pavel Klein, MD
-
Contact:
- Ivana Tyrlikova
- Phone Number: 301-530-9744
- Email: tyrlikovai@epilepsydc.com
-
Contact:
- Pavel Klein, MD
- Phone Number: 301-704-4925
- Email: kleinp@epilepsydc.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-65
- Stable focal epilepsy, with partial complex seizures including partial complex seizures with or without secondary generalization, partial simple seizures with a clear motor component with or without secondary generalization, and partial simple seizures with secondary generalization.
- Stable AED doses for at least 30 days
- Epilepsy duration for > 2 years
- Past/current treatment with > 4 AEDs. Vagal nerve stimulator treatment will be allowed and will not count as an AED. VNS setting must be stable for 3 months prior to enrollment.
- Seizure frequency of ≥1/month
Exclusion Criteria:
- Primary generalized epilepsy
- Simple partial seizures without motor components or secondary generalization
- Non-epileptic seizures
- Progressive neurological disease including neoplasm, CNS degenerative disorders including Alzheimer's disease, other forms of dementia
- Any systemic illness or unstable medical condition that might pose additional risk, including renal or liver disease, clinically uncontrolled cardiac disease, other unstable metabolic or endocrine disturbances, and active systemic cancer
- Change in the dose of any Antiepileptic Drug within 30 days prior to enrollment
- Psychosis within six months of enrollment.
- Active drug or alcohol dependence or any other factors that, in the opinion of the site investigators would interfere with adherence to study requirements;
- Pregnancy
- Use of any CNS-active investigational drugs within 3 months of enrollment.
- Inability or unwillingness of subject or legal guardian/representative to give written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Clobazam treatment
This will be an open label study comparing seizure frequency during 12 weeks of baseline observation period with seizure frequency during 16 weeks of clobazam adjunctive treatment
|
Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d.
schedule.
In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted.
Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
seizure freedom
Time Frame: 12 weeks
|
seizure freedom for 3 months of maintenance treatment with the highest tolerated clobazam dose
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
>75% seizure frequency reduction and median seizure frequency reduction for the whole treatment duration
Time Frame: 16 weeks
|
Secondary outcome measures will include >75% seizure frequency reduction and median seizure frequency reduction for the whole treatment duration and for the maintenance treatment period, comparing seizure frequency per 28 day periods during treatment vs. baseline.
|
16 weeks
|
median seizure frequency reduction for the whole treatment duration
Time Frame: 16 weeks
|
median seizure frequency reduction for the whole treatment duration
|
16 weeks
|
comparing seizure frequency per 28 day periods during treatment vs. baseline
Time Frame: 16 weeks
|
comparing seizure frequency per 28 day periods during treatment vs. baseline
|
16 weeks
|
quality of life questionnaire (QOLIE-31-P) scores
Time Frame: 16 weeks
|
16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Pavel Klein, M.D., Mid-Atlantic Epilepsy and Sleep Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Epilepsy
- Epilepsies, Partial
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- GABA Agents
- Anticonvulsants
- GABA-A Receptor Agonists
- GABA Agonists
- Clobazam
Other Study ID Numbers
- maes 007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Clobazam
-
Lundbeck LLCCompletedEpilepsy | Epilepsy, Generalized | SeizuresUnited States, Belarus, India, Australia, Lithuania
-
Lundbeck LLCCompletedEpilepsy | Epilepsy, Generalized | SeizuresUnited States
-
Boston Children's HospitalLundbeck LLCCompletedElectrical Status Epilepticus in SleepUnited States
-
University Hospital Inselspital, BerneCompleted
-
St. Joseph's Hospital and Medical Center, PhoenixH. Lundbeck A/SUnknownRefractory EpilepsyUnited States
-
University Hospital, GenevaCompleted
-
Lars Kristian MunckPierre and Marie Curie UniversityCompletedBile Acid Malabsorption | Chronic DiarrheaDenmark
-
Instituto de Investigação em ImunologiaButantan InstituteUnknownCancer. | Melanoma. | Ovarian Cancer. | Lung Cancer.Brazil
-
Hugo W. Moser Research Institute at Kennedy Krieger...Completed
-
H. Lundbeck A/STerminatedDravet SyndromeUnited States, Mexico